The strategy targets locally sourced, directly originated and privately negotiated flexible subordinated debt and equity investments in Asia Pacific middle market companies.
Asian version of our European flagship fund with an 18-year track record.
Head of Asia-Pacific Corporate
Head of Investment Office
To find out more about our flexible and sustainable solutions for both providers and users of capital, please contact us.
Flagship strategy with a 33-year track record
The strategy is a replica of ICG’s European Corporate but targets smaller mid-market transactions
The strategy is focused on creating and building life science companies addressing commercially attractive markets in diseases of
high unmet medical needs
Secondary strategy focusing on LP-led transactions
The focus of US Mid-Market is on delivering performance through differentiated sourcing, tailored capital solutions, operational intensity, and execution of buy-and-build strategies.
ICG’s Special Opportunities platform is a credit-led strategy that aims to achieve equity-like returns by taking advantage of market dislocations in the European mid-market
ICGSE is one of the largest investors globally that is focused exclusively on GP-led transactions
Invests in a diversified portfolio of senior secured loans to established companies
Focuses on investing in primarily sponsor-backed North American middle-market companies
Focuses on European senior direct lending
Providing private debt, and structured and private equity financing solutions, to private companies
We provide flexible and sustainable solutions to both providers and users of capital
Your form has been successfully submitted.